Thyrocare Technologies Limited has informed the Exchange about Transcript
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare reported a strong Q1 FY'26 with consolidated revenue of Rs. 193 crores, up 23% year-on-year, of which 21% was organic and 2% came from acquisitions (Polo, Vimta, Think Health). Standalone normalized EBITDA margin expanded 354 basis points year-on-year to 35%, driving normalized EBITDA up 42% to Rs. 63.35 crores and profit after tax up 62% to Rs. 38.06 crores. The franchise network grew to over 9,500 active quarterly franchisees (vs 8,145 in Q1 FY'25), with management targeting 1,200-1,500 net additions for the year, processing 46.9 million tests and serving 4.6 million patients. Key highlights included achieving India's first 100% NABL-accredited national lab chain, complaints per million dropping to 4 (from 6.4) with a Six Sigma target, and 192 healthcare partnerships in Tanzania. Alok Kumar Jagnani moves to API Group CFO with Vikram Gupta joining as new Thyrocare CFO.
Shares may react positively given the broad-based 23% revenue growth, sharp 354 bps EBITDA margin expansion, and 62% PAT growth, all ahead of industry growth. However, management declined to revise full-year guidance (sticking to mid-teens growth), citing a tough H2 base and continued reinvestment plans, including potential future acquisitions.